NEW YORK, Oct. 22 - Functional genomics company Galapagos Genomics and Procter & Gamble Pharmaceuticals have entered into a gene target-discovery and -validation research collaboration, the firms said on Monday.  

Terms of the two-year agreement call for Galapagos, of Mechelen, Belgium, to supply P&GP with adenoviral vectors that contain human genes selected by P&GP researchers. Galapagos will construct the recombinant adenoviruses using its PhenoSelect expression platform, the company said in a statement.